Relaxin immunoglobulin fusion proteins and methods of use

Patent metadata

Field	Value
Publication number	US-11161891-B2
Application number	US-201616060384-A
Country	US
Kind code	B2
Filing date	Dec 9, 2016
Priority date	Dec 9, 2015
Publication date	Nov 2, 2021
Grant date	Nov 2, 2021

Abstract

Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.

First claim

What is claimed is:

1. An immunoglobulin fusion protein comprising a therapeutic peptide inserted into a light chain complementarity determining region 3 (CDR3) of an antibody variable region comprising: a heavy chain comprising a CDR1 of SEQ ID NO: 72, a CDR2 of SEQ ID NO: 73, and a CDR3 sequence selected from SEQ ID NOS: 75-78; and a light chain comprising a CDR1 of SEQ ID NO: 89, a CDR2 of SEQ ID NO: 90, and a CDR3 sequence comprising at least three contiguous amino acids of SEQ ID NO: 91.

2. The immunoglobulin fusion protein of claim 1 , comprising SEQ ID NO: 75: SMITX(1)X(2)X(3)FDV; wherein X(1) is F, A, G, or P; X(2) is G, A, S, T, or P; and X(3) is G, A, V, L, or P.

3. The immunoglobulin fusion protein of claim 2 , wherein X(1) is F.

4. The immunoglobulin fusion protein of claim 2 , wherein X(2) is G.

5. The immunoglobulin fusion protein of claim 2 , wherein X(3) is G.

6. The immunoglobulin fusion protein of claim 1 , wherein the sequence selected from SEQ ID NOS: 75-78 comprises a sequence selected from SEQ ID NOS: 79-88.

7. The immunoglobulin fusion protein of claim 6 , comprising the SEQ ID NO: 79.

8. A method comprising administering to a subject in need thereof the immunoglobulin fusion protein of claim 1 .

9. An antibody comprising the immunoglobulin fusion protein of claim 1 and a Fc domain at least 90% homologous to SEQ ID NO: 98.

10. The antibody of claim 9 , comprising SEQ ID NO: 16.

11. An antibody comprising a Fc region having SEQ ID NO: 98, and an antibody variable region comprising a heavy chain comprising a sequence at least about 95% identical to SEQ ID NO: 16, and a light chain comprising a therapeutic peptide and a sequence at least about 95% identical to SEQ ID NO: 9.

12. The antibody of claim 11 , wherein the therapeutic peptide is positioned within the antibody variable region.

13. The antibody of claim 11 , wherein the therapeutic peptide is inserted into the antibody variable region.

Assignees

• Scripps Research Inst

Inventors

• Wang Feng
• Liu Yan
• Wang Ying
• Fu Guangsen
• Schultz Peter G

Classifications

• C07K16/11

  Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K14/64 Primary

  Relaxins · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title